Bromocriptine formulations
The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
1. A dosage form comprising
micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet;
wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and
wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and
wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
2. The dosage form of claim 1 , wherein the micronized bromocriptine mesylate has a Dv90 of less than about 10 μm.
3. The dosage form of claim 2 , wherein the micronized bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.
4. The dosage form of claim 1 , wherein the micronized bromocriptine mesylate has a Dv90 of less than about 20 μm.
5. The dosage form of claim 4 , wherein the micronized bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.
6. The dosage form of claim 4 wherein the micronized bromocriptine mesylate has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 μm.
7. The dosage form of claim 1 wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 20 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
8. A dosage form comprising
micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet;
wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and
wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and
wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
9. A dosage form comprising
micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet;
wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and
wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein
said dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following administration of the dosage form to the subject under high fat fed conditions.
10. The dosage form of claim 1 wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per said oral tablet.
11. A dosage form comprising
micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet;
wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and
wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and
wherein the oral tablet has a dissolution profile wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
12. The dosage form of claim 11 wherein the bromocriptine mesylate has a particle size distribution with a Dv90 of less than about 20 μm.
13. The dosage form of claim 9 , wherein the dosage form exhibits the pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine in the subject is between about 30 and about 60 minutes following administration of the dosage form to the subject under fasting conditions.
14. The dosage form of claim 9 , wherein the dosage form exhibits the pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine in the subject is between about 90 and about 120 minutes following administration of the dosage form to the subject under high fat fed conditions.
15. The dosage form of claim 13 , wherein the bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per said tablet.
16. The dosage form of claim 14 , wherein the bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per said tablet.
17. The dosage form of claim 12 , wherein the tablet provides a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes, when the tablet is tested by USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
18. The dosage form of claim 12 , wherein the bromocriptine mesylate has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 μm.
19. The dosage form of claim 17 , wherein the tablet provides a dissolution profile wherein at least about 95% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
20. The dosage form of claim 17 , wherein the tablet provides a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 20 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
21. The dosage form of claim 17 , wherein the tablet provides a dissolution profile wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C.
22. A method of improving glycemic control in a type 2 diabetes patient, comprising
administering the dosage form of claim 1 to the patient.
23. The method of claim 22 , wherein the tablet comprises bromocriptine mesylate in an amount that provides a dose of about 0.8 mg of bromocriptine per said tablet.
24. The method of claim 22 , wherein the bromocriptine mesylate is administered to the patient in an amount that provides a daily dose of about 0.8 mg to about 4.8 mg of bromocriptine.
25. The method of claim 22 , wherein the administering of the dosage form to the patient produces a pharmacokinetic profile comprising a time to maximum plasma concentration (T max ) of bromocriptine of between about 30 and about 60 minutes under fasting conditions or a T max of bromocriptine of between about 90 and about 120 minutes under high fat fed conditions.
26. The method of claim 22 , wherein the micronized bromocriptine mesylate has a Dv90 of less than about 20 μm.
27. The method of claim 26 , wherein the micronized bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.
28. A method of improving glycemic control in a type 2 diabetes patient, comprising administering the dosage form of claim 8 to the patient.
29. A method of improving glycemic control in a type 2 diabetes patient, comprising administering the dosage form of claim 9 to the patient.
30. A method of improving glycemic control in a type 2 diabetes patient, comprising administering the dosage form of claim 11 to the patient.